Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Immunome Inc. Director's Dealing 2025

Dec 31, 2025

32238_dirs_2025-12-30_1e48fee9-5d3a-4426-a957-abd5c6eef3ac.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immunome Inc. (IMNM)
CIK: 0001472012
Period of Report: 2025-12-30

Reporting Person: SIEGALL CLAY B (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-12-30 Common Stock P 4729 $21.15 Acquired 665254 Direct